Trials / Completed
CompletedNCT04949269
A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants
A Phase 1, Open-label, Crossover Study to Evaluate the Pharmacokinetics of Deucravacitinib (BMS-986165) Administered as Various Solid Tablet Formulations in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the drug levels of deucravacitinib after oral administration in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | Specified dose on specified days |
| DRUG | Famotidine | Specified dose on specified days |
Timeline
- Start date
- 2021-07-20
- Primary completion
- 2022-01-03
- Completion
- 2022-01-03
- First posted
- 2021-07-02
- Last updated
- 2022-03-11
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04949269. Inclusion in this directory is not an endorsement.